ScholarLens Back to search
2001•Zhongguo linchuang yaolixue yu zhiliaoxueRequires access

Clinical study of leflunomide in the treatment of patients with active rheumatoid arthritis

Xiang Li

Open publisher page 0 citations

Abstract

Aim To compare the effectiveness and safety of leflunomide(LEF) with those of methotrexate(MTX) in patients with active rheumatoid arthritis(RA). Methods 95 RA patients were randomly assigned to receive LEF or MTX. The patients in the treated group received LEF 20 mg·d -1 and in the controlled group who received MTX 15 mg/wk totally 12 weeks. Results The total effective rates of the treated group and the controlled group were 90.0 %(n =50 ) and 95.6 %(n =45 ) respectively. There was no statistical significance between the two groups in the effectiveness (P0.05).The adverse reaction rate was 14.0% (7 case) in the treated group and 15.6%(7 cases) in the controlled group. There was no significance difference between the two groups (P=0.83). But the adverse reactions were more tolerable in LEF group than in MTX group. Conclusion This study suggests that LEF is an effective and more safe drug for active rheumatoid arthritis in our country.

About this research paper

What this paper is about

Aim To compare the effectiveness and safety of leflunomide(LEF) with those of methotrexate(MTX) in patients with active rheumatoid arthritis(RA). Methods 95 RA patients were randomly assigned to receive LEF or MTX. The patients in the treated group received LEF 20 mg·d -1 and in the controlled group who received MTX 15 mg/wk totally 12 weeks. Results The total effective rates of the treated group and the controlled group were 90.0 %(n =50 ) and 95.6 %(n =45 ) respectively. There was no statistical significance between the two groups in the effectiveness (P0.05).The adverse reaction rate was 14.0% (7 case) in the treated group and 15.6%(7 cases) in the controlled group. There was no significance difference between the two groups (P=0.83). But the adverse reactions were more tolerable in LEF group than in MTX group. Conclusion This study suggests that LEF is an effective and more safe drug for active rheumatoid arthritis in our country.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Aim To compare the effectiveness and safety of leflunomide(LEF) with those of methotrexate(MTX) in patients with active rheumatoid arthritis(RA). Methods 95 RA patients were randomly assigned to receive LEF or MTX. The patients in the treated group received LEF 20 mg·d -1 and in the controlled group who received MTX 15 mg/wk totally 12 weeks. Results The total effective rates of the treated group and the controlled group were 90.0 %(n =50 ) and 95.6 %(n =45 ) respectively. There was no statistical significance between the two groups in the effectiveness (P0.05).The adverse reaction rate was 14.0% (7 case) in the treated group and 15.6%(7 cases) in the controlled group. There was no significance difference between the two groups (P=0.83). But the adverse reactions were more tolerable in LEF group than in MTX group. Conclusion This study suggests that LEF is an effective and more safe drug for active rheumatoid arthritis in our country.

Key concepts: Leflunomide, Rheumatoid arthritis, Medicine, Methotrexate, Adverse effect, Internal medicine, Statistical significance, Drug reaction

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical study of leflunomide in the treatment of patients with active rheumatoid arthritis — Research Paper | ScholarLens